These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25888887)

  • 1. Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis.
    Tanaka A; Tsukamoto H; Mitoma H; Kiyohara C; Ueda N; Ayano M; Ohta S; Kimoto Y; Akahoshi M; Arinobu Y; Niiro H; Tada Y; Horiuchi T; Akashi K
    Arthritis Res Ther; 2015 Feb; 17(1):27. PubMed ID: 25888887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F; Shu XM; Wang DX; Xie Y; Wang GC
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].
    Chen F; Shu XM; Wang DX; Wang GC; Lu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):204-8. PubMed ID: 22516988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody.
    Shanshan L; Yamei Z; Ling Z; Xin L; Guochun W
    Clin Rheumatol; 2022 Mar; 41(3):757-763. PubMed ID: 34718893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
    Shu X; Peng Q; Lu X; Wang G
    PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease.
    Lou Y; Zheng Y; Fan B; Zhang L; Zhu F; Wang X; Chen Z; Tan X; Wei Q
    BMC Pulm Med; 2020 Jul; 20(1):196. PubMed ID: 32680574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease.
    Matsuda S; Kotani T; Ishida T; Fukui K; Fujiki Y; Suzuka T; Nagai K; Hata K; Shoda T; Isoda K; Ito Y; Makino S; Takeuchi T; Arawaka S
    Rheumatology (Oxford); 2020 Feb; 59(2):310-318. PubMed ID: 31321420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF.
    Tóth NM; Müller V; Nagy T; Polivka L; Horváth P; Bohács A; Eszes N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
    Ihn H; Asano Y; Kubo M; Yamane K; Jinnin M; Yazawa N; Fujimoto M; Tamaki K
    Rheumatology (Oxford); 2002 Nov; 41(11):1268-72. PubMed ID: 12421999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.
    Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H
    Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker.
    Hanaoka M; Katsumata Y; Kawasumi H; Kawaguchi Y; Yamanaka H
    Mod Rheumatol; 2019 Jul; 29(4):625-632. PubMed ID: 30484723
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis.
    Zhu D; Qiao J; Tang S; Pan Y; Li S; Yang C; Fang H
    Rheumatology (Oxford); 2021 Aug; 60(8):3896-3903. PubMed ID: 33398346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.